Evaluation of Concurrent Endometri̇al Cancser i̇n Pati̇ents Wi̇th Endometrial Hyperplasia; 10 Years Experience as a Terti̇ary Center

Abstract

Objective: We aimed to determine the incidence of simultaneous endometrial cancer in patients with endometrial hyperplasia who underwent surgical treatment. Material and Methods: Our study was designed retrospectively. The medical data of patients who was diagnosed endometrial hyperplasia (EH) by the endometrial biopsy and accepted surgical treatment were examined and collected between 2007-2017 at the gynecologic oncology depertmant of Eskişehir Osmangazi University (ESOGÜ). The data of 522 patients with endometrial hyperplasia as a result of endometrial sampling were evaluated. Due to 187 patients received medical treatment, 35 patients lacked medical data and 15 patients suspected endometrial CA were excluded from the study. A total of 285 patients with endometrial hyperplasia were included in the study. Results: Of the 285 patients included in the study, 64 (22.4%) were simple hyperplasia, 31 (10.8%) were simple atypia hyperplasia, 72 (25.2%) were complex hyperplasia and 118 (41.4%) were complex atypia hyperplasia. Endometrial hyperplasia could not be detected in 84 (29.4%) patients after a final pathology. We found endometrial cancer in 36 (12.6%) patients and endometrial hyperplasia in 165 (57.8%) patients. We found 1 (1.5%) patient EC in simple hyperplasia. EC was detected in 1 (3.2%) patient in SAH. 6 patients (8.3%) had EC in CH. 28 (23.7%) EC's were detected in patients with CAH. According to the 2014 WHO classification system, Concurrent endometrial cancer rates were determined as AEH 19.4% and EH without atypia was 5.1%. Conclusion: Concurrent EC ratio in simple hyperplasia was 5.1% this rate was found to be 8.3% in CH. Management of patients with endometrial hyperplasia without atypia If medical treatment is to be chosen, these rates should be considered and it is recommended to consider all risk factors for EC.